Table 2.

Correlations of secretome-derived cytokine levels with clinical parameters

		IL-2	IL-23	IL-31	CCL19 (MIP-3β)	CXCL13 (BLC)	CXCL10 (IP-10)	TIM-1/ KIM-1	GM-CSF
Lymphocytic focus score	r	0.333	0.157	0.212	0.468	0.431	0.568	0.089	0.150
	p-value	0.111	0.463	0.321	0.021	0.035	0.004	0.680	0.484
% IgG+/IgM+ plasma cells	r	0.325	0.044	0.107	0.101	0.140	0.299	0.124	0.276
	P value	0.151	0.850	0.643	0.663	0.546	0.188	0.592	0.226
Schirmer test	r	−0.590	−0.298	−0.451	−0.258	−0.314	−0.441	−0.338	−0.453
	P value	0.010	0.230	0.060	0.301	0.204	0.067	0.171	0.059
ESSDAI	r	−0.005	0.215	0.286	0.084	0.138	0.330	0.392	0.118
	P value	0.982	0.324	0.186	0.704	0.530	0.125	0.064	0.592
ESSPRI	r	0.118	−0.156	−0.186	0.022	−0.392	0.184	−0.11	0.244
	p-value	0.700	0.610	0.544	0.942	0.185	0.548	0.971	0.423
Serum IgG	r	0.259	0.442	0.411	−0.018	0.360	0.427	0.356	0.427
	P value	0.232	0.035	0.052	0.934	0.092	0.042	0.096	0.042
ESR	r	0.150	0.154	0.439	0.410	0.331	0.131	0.400	0.081
	P value	0.493	0.483	0.036	0.052	0.122	0.552	0.058	0.715
Anti-Ro/SSA pos vs neg	P value	0.192	0.052	0.027	0.881	0.081	0.061	0.032	0.153

Correlations between cytokine concentrations and clinical parameters in the patients with pSS are shown.

Spearman r and p values are represented.

Mann-Whitney U test was used to test if cytokine levels significantly differed between anti-SSA+ and anti-SSA- patients with pSS. Significant correlations (p<0.05) are depicted in bold.

Cytokines that did not significantly correlate with any clinical parameter (sIL-2R) or of which correlation have been published (sIL-7Rα, CCL25) are excluded from this table. No correlations with anti-La/SSB autoantibodies or C4 levels were found.

ESR, erythrocyte sedimentation rate; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; SSA, Sjögren’s syndrome antigen A; SSB, Sjögren’s syndrome antigen B; nSS, non-Sjögren’s sicca; pSS, primary Sjögren’s syndrome.